Literature DB >> 9242499

Broad-spectrum sunscreens provide greater protection against ultraviolet-radiation-induced suppression of contact hypersensitivity to a recall antigen in humans.

D L Damian1, G M Halliday, R S Barnetson.   

Abstract

This study investigates the extent to which sunscreens protect humans from ultraviolet (UV)-radiation-induced immunosuppression. In the presence of solar-simulated UV, three sunscreens with differing UVA transmission were assessed for their ability to protect the contact hypersensitivity (CHS) response to nickel of 16 nickel-allergic subjects. The sunscreens contained 2-ethylhexyl para-methoxycinnamate (cinnamate), cinnamate with oxybenzone, or cinnamate with zinc oxide, respectively. All had sun protection factors of 10 and hence inhibited UV erythema to similar extents. Volunteers were irradiated on their backs with suberythemal UV daily for 5 d after application of the sunscreens and their base lotion to different sites. Nickel-containing patches were then applied to both UV-treated sites and adjacent, unirradiated control sites. Erythema caused by nickel CHS at each site was quantitated 72 h later with a reflectance erythema meter. In comparison of the nickel reactions of irradiated and unirradiated skin, there was 35% mean immunosuppression in unprotected UV-treated skin. Significant immunosuppression also occurred at sites irradiated through the narrow-spectrum cinnamate-only sunscreen but was prevented by the two broad-spectrum sunscreens. To determine whether UV-induced suppression of the nickel response is specific for cell-mediated immunity or reflects suppression of nonspecific inflammation, a further 16 subjects were patch-tested with a skin irritant, sodium lauryl sulfate (SLS), following a sunscreen and irradiation protocol identical to that of the nickel volunteers. UV had no significant effect on SLS responses. We conclude that nickel patch testing is a valid means of assessing UV-induced immunosuppression in humans and that even with suberythemal UV, immune protection was provided only by sunscreens filtering both UVA and UVB.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242499     DOI: 10.1111/1523-1747.ep12319200

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Promoting sun safety among US Postal Service letter carriers: impact of a 2-year intervention.

Authors:  Joni A Mayer; Donald J Slymen; Elizabeth J Clapp; Latrice C Pichon; Laura Eckhardt; Lawrence F Eichenfield; John P Elder; James F Sallis; Martin A Weinstock; April Achter; Cynthia Balderrama; Gabriel R Galindo; Sam S Oh
Journal:  Am J Public Health       Date:  2007-01-31       Impact factor: 9.308

Review 2.  Roles of the immune system in skin cancer.

Authors:  S Rangwala; K Y Tsai
Journal:  Br J Dermatol       Date:  2011-11       Impact factor: 9.302

3.  Heme oxygenase induction mediates the photoimmunoprotective activity of UVA radiation in the mouse.

Authors:  V E Reeve; R M Tyrrell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

4.  Enzyme plus light therapy to repair DNA damage in ultraviolet-B-irradiated human skin.

Authors:  H Stege; L Roza; A A Vink; M Grewe; T Ruzicka; S Grether-Beck; J Krutmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 5.  UV-induced immune suppression and photocarcinogenesis: chemoprevention by dietary botanical agents.

Authors:  Santosh K Katiyar
Journal:  Cancer Lett       Date:  2007-03-26       Impact factor: 8.679

6.  Suppression of an established immune response by UVA--a critical role for mast cells.

Authors:  Stephen E Ullrich; Dat X Nghiem; Polina Khaskina
Journal:  Photochem Photobiol       Date:  2007 Sep-Oct       Impact factor: 3.421

Review 7.  Photoimmunology--illuminating the immune system through photobiology.

Authors:  Justin Leitenberger; Heidi T Jacobe; Ponciano D Cruz
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 11.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.